This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The study hypothesis is that VX770, a novel compound in development for the treatment of cystic fibrosis (CF), is safe and well tolerated by CF patients.
Showing the most recent 10 out of 724 publications